

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning on line page 19, line 20 to page 20, line 10 with the following rewritten paragraph:

61
The method and formulations of the invention are useful for treating humans and animals suffering from or prone to certain lung conditions, disorders or diseases associated with or caused by local inflammation. For example, the compositions find utility in the prevention or treatment of local inflammation of the lung seen in atopic and non-atopic asthma and COPD. COPD includes chronic bronchitis and emphysema. Interstitial lung disease (ILD) includes fibrosing alveolitis, ~~sarcoidosis~~ sarcoidosis and fibrotic lung diseases. The cause of ILD is unknown but may be associated with exposure to inorganic and organic dusts or radiation, including occupational and environmental exposure. Hypersensitivity alveolitis caused by allergens can lead to ILD; idiopathic ILD is of an unknown origin and likely includes autoimmune alveolitis. Occupational inflammatory diseases of the lung that can result in ILD include asbestosis, pulmonary berylliosis, coal worker's pneumoconiosis, silicosis and byssinosis (cotton dust). The invention is additionally useful for the chemoprevention of the debilitating fibrotic involvement of ILD without the potential disadvantages associated with long-term corticosteroid therapy, when treatment is instigated before or early in the pathogenesis of fibrosis, e.g., at the stage or prior to the stage when the lung inflammation is an asymptomatic pathophysiologic process.
